Avoiding the Supply Risk From Serialisation With CMOs

For many pharmaceutical companies, use of contract manufacturing organisations (CMO) to package commercial products is an integral part of their supply chain. For virtual companies, it may be the only way their products are packaged.

Serialisation legislation in the US, EU, and many other countries means that without the successful and timely implementation and integration of CMO serialisation capabilities, pharmaceutical companies will no longer be able to supply products. The complex, evolving, immature, and increasingly resource-constrained area of serialisation means that the risks of significant supply interruptions are high.

Download this free whitepaper to find out more about serialisation, including the flexibility CMOs have, the decision-making process, and the use of risk management to focus resource applications.